Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker CTMX
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | SCHEDULE 13G | CTMX CytomX Therapeutics, Inc. | State Street Corporation | 9.03M | 4.1% | SCHEDULE 13G ↗ |
| Oct 28, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Bank of America Corp /DE/ | 11.87M | 5.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Yue Tang | 0 | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Kynam Capital Management GP, LLC | 0 | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Kynam Capital Management, LP | 0 | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Steven A. Cohen | 7.81M | 3.6% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Point72 Capital Advisors, Inc. | 7.81M | 3.6% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Point72 Asset Management, L.P. | 7.81M | 3.6% | SCHEDULE 13G/A ↗ |
| Aug 7, 2026 | SCHEDULE 13G | CTMX CytomX Therapeutics, Inc. | State Street Corporation | 11.75M | 5.4% | SCHEDULE 13G ↗ |
| Aug 3, 2026 | SCHEDULE 13G | CTMX CytomX Therapeutics, Inc. | Bank of America Corp /DE/ | 15.13M | 7.0% | SCHEDULE 13G ↗ |
| Jul 27, 2026 | SCHEDULE 13G | CTMX CytomX Therapeutics, Inc. | BlackRock, Inc. | 16.55M | 7.6% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Yue Tang | 0 | 6.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Kynam Capital Management GP, LLC | 0 | 6.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Kynam Capital Management, LP | 0 | 6.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Bong Y. Koh | 9.98M | 4.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Nimish Shah | 9.98M | 4.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | VHCP Management EG, LLC | 9.98M | 4.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | VHCP Management III, LLC | 9.98M | 4.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Venrock Healthcare Capital Partners EG, L.P. | 9.98M | 4.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | VHCP Co-Investment Holdings III, LLC | 9.98M | 4.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Venrock Healthcare Capital Partners III, L.P. | 9.98M | 4.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Juliet Tammenoms Bakker | 15.29M | 7.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Patrick G. Enright | 15.29M | 7.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Longitude 103.8 East, L.P. | 2.83M | 1.3% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Longitude 103.8 East Partners, LLC | 2.83M | 1.3% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Longitude Venture Partners V, L.P. | 12.46M | 5.7% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Longitude Capital Partners V, LLC | 12.46M | 5.7% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Perceptive Life Sciences Master Fund, Ltd. | 10.10M | 4.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Joseph Edelman | 10.10M | 4.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Perceptive Advisors LLC | 10.10M | 4.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Brian Liu | 1.09M | 0.5% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Seven Fleet Capital Management GP LLC | 1.09M | 0.5% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Seven Fleet Capital Management LP | 1.09M | 0.5% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Seven Fleet Master Fund LP | 1.09M | 0.5% | SCHEDULE 13G/A ↗ |
| Apr 16, 2026 | SCHEDULE 13G | CTMX CytomX Therapeutics, Inc. | Steven A. Cohen | 10.86M | 5.0% | SCHEDULE 13G ↗ |
| Apr 16, 2026 | SCHEDULE 13G | CTMX CytomX Therapeutics, Inc. | Point72 Capital Advisors, Inc. | 10.86M | 5.0% | SCHEDULE 13G ↗ |
| Apr 16, 2026 | SCHEDULE 13G | CTMX CytomX Therapeutics, Inc. | Point72 Asset Management, L.P. | 10.86M | 5.0% | SCHEDULE 13G ↗ |
| Mar 26, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | The Vanguard Group | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Mar 4, 2026 | SCHEDULE 13G | CTMX CytomX Therapeutics, Inc. | Yue Tang | 8.97M | 5.3% | SCHEDULE 13G ↗ |
| Mar 4, 2026 | SCHEDULE 13G | CTMX CytomX Therapeutics, Inc. | Kynam Capital Management GP, LLC | 8.97M | 5.3% | SCHEDULE 13G ↗ |
| Mar 4, 2026 | SCHEDULE 13G | CTMX CytomX Therapeutics, Inc. | Kynam Capital Management, LP | 8.97M | 5.3% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Tang Capital Partners IV, Inc | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Tang Capital Partners III, Inc | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Tang Capital Partners International, LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Tang Capital Partners, LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Kevin Tang | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Tang Capital Management, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | OrbiMed Advisors LLC | 3.53M | 2.1% | SCHEDULE 13G/A ↗ |
| Feb 5, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | Abigail P. Johnson | 24.69M | 14.6% | SCHEDULE 13G/A ↗ |
| Feb 5, 2026 | SCHEDULE 13G/A (amended) | CTMX CytomX Therapeutics, Inc. | FMR LLC | 24.69M | 14.6% | SCHEDULE 13G/A ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:26 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances